Thursday, January 31, 2019 8:54:30 AM
Email Print Friendly Share
January 31, 2019 08:30 ET | Source: Canbiola, Inc.
HICKSVILLE, NY, Jan. 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, concentrate and water, announced today the launch and availability of a revolutionary Sustained Acoustic Medicine (“SAM”) wellness solution. SAM, along with its proprietary CBD Gel Capture Patches, is proven in accelerating tissue healing and chronic pain reduction and is reimbursable by health insurance companies.
The SAM Pro 2.0 is the first and only FDA cleared wearable low-intensity ultrasound device delivering multi-hour treatment to accelerate healing and improve function for musculoskeletal injuries (muscle, tendon, ligament) and reducing chronic pain (without opioid pain medication).
Canbiola and its Duramed subsidiary have attained exclusive distribution of SAM Pro 2.0 in the United States for no-fault insurance. Under its agreement with Sam International and ZetrOZ Systems, Canbiola is committed to purchasing 100 units per month starting in January and ramping to 150 units per month by June, for a total of 1,650 units for 2019.
Canbiola’s marketing strategy is to provide equipment and services to both medical offices as well as direct to consumer. We are presently billing and collecting from the insurance companies at $58 per day per unit. Given discussions with the medical community, including doctors and patients, the Company believes the patient will use the Sam unit and pads for an average of 35 days per cycle and that each unit will cycle an estimated 7 times per year. Thus, each unit potentially provides $14,210 in gross rental revenue per year.
Canbiola Chief Executive Officer Marco Alfonsi, commented, “We are very excited in achieving this milestone of launching a revolutionary solution that addresses a much-needed void in the market to accelerate tissue healing and chronic pain reduction. Our proprietary CBD gels coupled with the unique SAM delivery system, which we have exclusive U.S. rights within no-fault insurance to, will potentially drive our acceleration of both revenues and gross margins over the next twelve months.”
About Canbiola, Inc.
Canbiola, Inc. (OTCQB: CANB) is a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrate and water. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. For more information about Canbiola, Inc., please visit: https://canbiola.com
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.
CONTACT INFORMATION:
Canbiola Investor Relations
Email: IR@canbiola.com
Phone: (516) 595-9544
Website: http://www.canbiola.com
Follow us on Twitter and Facebook
Recent CANB News
- Can B Corp. Secures Ownership and Control of Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million • InvestorsHub NewsWire • 03/11/2024 12:34:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 10:15:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:02:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:38:08 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 04:52:26 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/08/2024 06:08:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 12:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 03:36:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 10:15:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:18:08 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/13/2023 02:44:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 06:24:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 08:57:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:12:43 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:41:28 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM